文献速递前列腺癌

挽救性前列腺切除术后生化复发与转移无生存作为总生存替代终点的评估

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.
PubMed 文献 · BJU Int · 2026-06-15

该回顾性多中心队列纳入879例接受挽救性前列腺切除术的复发非转移性激素敏感前列腺癌患者,评估生化复发无生存(BRFS)和转移无生存(MFS)能否作为总生存(OS)的替代终点。个体水平分析显示MFS与OS强相关(Kendall's τ 0.85),BRFS关联不足(τ 0.63);中心水平分析中3年BRFS和MFS均不能充分预测5年OS,结论认为BRFS不宜作为替代终点,MFS需前瞻性验证。

要点

  • 个体水平MFS与OS强相关(τ 0.85),BRFS关联不足(τ 0.63)。
  • 中心水平3年BRFS和3年MFS均不能充分预测5年OS。
  • BRFS不应作为挽救性前列腺切除术后的替代终点。

核心结论

  • BRFS不应在挽救性前列腺切除术背景下用作替代终点。
  • MFS与OS的关联需未来前瞻性研究进一步验证。
  • 生活质量和治疗相关毒性等患者报告结局应与OS并行考虑。

研究设计与样本

  • 回顾性数据集筛选出879例复发、非转移、激素敏感前列腺癌患者,在13个中心接受挽救性前列腺切除术。
  • 替代终点评估采用两阶段法:个体水平拟合Clayton copula模型估计Kendall's τ(τ>0.7提示强关联),中心水平拟合加权线性回归以3年BRFS和MFS预测5年OS。
  • 两步分析纳入759例用于BRFS(366个事件),476例用于MFS(137个事件)。

主要发现

  • BRFS分析中位随访37个月(95%CI 36-42个月),MFS分析中位随访34个月(95%CI 31-37个月)。
  • 个体水平MFS与OS强关联(Kendall's τ 0.85,95%CI 0.82-0.88),BRFS未显示强关联(Kendall's τ 0.63,95%CI 0.56-0.69)。
  • 中心水平3年BRFS预测5年OS的R2=0.15,斜率=0.34,P=0.2;3年MFS的R2=0.21,斜率=0.26,P=0.14。

关键数值与推荐

  • 个体水平强关联阈值定义为Kendall's τ>0.7。
  • 中心水平分析中3年BRFS和3年MFS对5年OS的预测均无充分解释力(P值分别为0.2和0.14)。

临床怎么用

  • 在挽救性前列腺切除术后,不应将BRFS作为总生存的替代终点用于临床决策或试验设计。
  • MFS作为替代终点证据尚不充分,需等待前瞻性验证后再考虑应用。
  • 评估治疗获益时应同时关注生活质量和治疗相关毒性等患者报告结局。

局限性

  • 中心水平分析基于单臂关联而非跨臂治疗效应替代。
  • 数据为回顾性收集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate biochemical recurrence-free survival (BRFS) and metastasis-free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). PATIENTS AND METHODS: Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non-metastatic, hormone-sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two-stage approach: (i) at the individual-patient level by fitting Clayton copula models and estimating Kendall's τ ( τ >0.7 indicating a strong association) and (ii) at the centre level, by fitting weighted linear regression of 5-year OS on 3-year BRFS and MFS. RESULTS: The two-step analysis included 759 patients for BRFS (366 events) and 476 for MFS (137 events), with median follow-up of 37 months (95% confidence interval [CI] 36-42 months) and 34 months (95% CI 31-37 months), respectively. At the individual-patient level, MFS showed a strong association with OS (Kendall's τ 0.85, 95% CI 0.82-0.88), which was not observed for BRFS (Kendall's τ 0.63, 95% CI 0.56-0.69). At the centre level, neither 3-year BRFS (R2 = 0.15; slope = 0.34, P = 0.2) nor 3-year MFS (R2 = 0.21; slope = 0.26, P = 0.14) predicted 5-year OS with sufficient explanatory power. Limitations include the fact that centre-level analysis was based on single-arm associations rather than on treatment-effect surrogacy across arms, and retrospective data collection. CONCLUSIONS: The BRFS should not be used as a surrogate endpoint in the sRP setting. MFS requires further validation in future prospective studies to confirm its association with OS. Patient-reported outcomes, such as quality-of-life and treatment-related toxicity, should be considered in parallel with OS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Roessler N, Nowicka Z, Miszczyk M, et al. Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy. BJU Int. 2026. PMID: 42298374. doi:10.1111/bju.70352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。